CN117177971A - 含氮杂环类化合物、其制备方法及其在医药上的应用 - Google Patents

含氮杂环类化合物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN117177971A
CN117177971A CN202280027629.8A CN202280027629A CN117177971A CN 117177971 A CN117177971 A CN 117177971A CN 202280027629 A CN202280027629 A CN 202280027629A CN 117177971 A CN117177971 A CN 117177971A
Authority
CN
China
Prior art keywords
compound
cancer
formula
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280027629.8A
Other languages
English (en)
Chinese (zh)
Inventor
李心
董怀德
蔡国栋
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN117177971A publication Critical patent/CN117177971A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280027629.8A 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用 Pending CN117177971A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202110565410 2021-05-24
CN2021105654100 2021-05-24
CN202110694022 2021-06-22
CN2021106940222 2021-06-22
CN202110856289 2021-07-28
CN2021108562897 2021-07-28
CN202210198679 2022-03-02
CN2022101986794 2022-03-02
PCT/CN2022/094612 WO2022247816A1 (zh) 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN117177971A true CN117177971A (zh) 2023-12-05

Family

ID=84229501

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280027629.8A Pending CN117177971A (zh) 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用

Country Status (11)

Country Link
US (1) US20240287094A1 (https=)
EP (1) EP4349836A4 (https=)
JP (1) JP2024519188A (https=)
KR (1) KR20240012437A (https=)
CN (1) CN117177971A (https=)
AU (1) AU2022280845A1 (https=)
BR (1) BR112023022496A2 (https=)
CA (1) CA3219858A1 (https=)
MX (1) MX2023013890A (https=)
TW (1) TW202313630A (https=)
WO (1) WO2022247816A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
AU2023209820B2 (en) 2022-01-21 2024-10-10 Xinthera, Inc. Parp1 inhibitors and uses thereof
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
FI4497438T3 (fi) 2022-04-28 2025-10-20 Xinthera Inc Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
CN120035596A (zh) * 2022-11-23 2025-05-23 江苏恒瑞医药股份有限公司 一种含氮杂环类化合物的可药用盐、晶型及制备方法
AU2024286996A1 (en) 2023-06-08 2026-01-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for formamide compounds
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2020098774A1 (zh) * 2018-11-16 2020-05-22 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
WO2021013735A1 (en) * 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
CN116018132A (zh) 2020-06-24 2023-04-25 Itf研究制药有限公司 软明胶胶囊
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
CN119110801A (zh) * 2022-05-07 2024-12-10 南京明德新药研发有限公司 选择性抑制parp1的氟代喹喔啉酮衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2020098774A1 (zh) * 2018-11-16 2020-05-22 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
WO2021013735A1 (en) * 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors

Also Published As

Publication number Publication date
CA3219858A1 (en) 2022-12-01
BR112023022496A2 (pt) 2024-01-16
EP4349836A1 (en) 2024-04-10
US20240287094A1 (en) 2024-08-29
EP4349836A4 (en) 2024-10-30
JP2024519188A (ja) 2024-05-08
AU2022280845A1 (en) 2023-12-14
TW202313630A (zh) 2023-04-01
WO2022247816A1 (zh) 2022-12-01
KR20240012437A (ko) 2024-01-29
MX2023013890A (es) 2023-12-11

Similar Documents

Publication Publication Date Title
CN117177971A (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN116262759B (zh) 嘧啶三环类化合物及其制备方法和医药用途
CN117203207A (zh) 桥环类化合物、其制备方法及其在医药上的应用
CN119365465A (zh) 稠环类化合物、其制备方法及其在医药上的应用
KR101829940B1 (ko) 프탈라지논 케톤 유도체, 이의 제조방법, 및 이의 약학적 용도
CN115368383A (zh) 稠合含氮杂环类化合物、其制备方法及其在医药上的应用
CN114423760A (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN120230123A (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN115403595A (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN120365289A (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN118339157A (zh) 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN119365468A (zh) 稠合二环类化合物、其制备方法及其在医药上的应用
CN119365458A (zh) 稠合三环类化合物、其制备方法及其在医药上的应用
CN118556044A (zh) 稠杂环类化合物、其制备方法及其在医药上的应用
CN112996783A (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN115867552B (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN115836077B (zh) 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
CN115835863B (zh) 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
CN113754685B (zh) 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用
EA051431B1 (ru) Азотсодержащее гетероциклическое соединение, способ его получения и его применение в качестве ингибитора parp1
CN113135942B (zh) 稠合嘧啶类衍生物、其制备方法及其在医药上的应用
CN119161325A (zh) 内酰胺类化合物、其制备方法及其在医药上的应用
EP4495119A1 (en) Fused heterocyclic compound, and preparation method therefor and medical use thereof
TW202229281A (zh) 嘌呤酮類化合物、其製備方法及其在醫藥上的應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103915

Country of ref document: HK